PORTON PHARMA SOLUTIONS LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.89 CNY | +2.36% |
|
-3.00% | -44.77% |
| Sales 2024 * | 3.05B 421M | Sales 2025 * | 4.53B 625M | Capitalization | 7.58B 1.05B |
|---|---|---|---|---|---|
| Net income 2024 * | 399M 55.01M | Net income 2025 * | 555M 76.51M | EV / Sales 2024 * | 2.49 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.67 x |
| P/E ratio 2024 * |
19
x | P/E ratio 2025 * |
13.7
x | Employees | 4,915 |
| Yield 2024 * |
1.76% | Yield 2025 * |
2.2% | Free-Float | 56.91% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.36% | ||
| 1 week | -3.00% | ||
| Current month | -5.83% | ||
| 1 month | -20.22% | ||
| 3 months | -28.11% | ||
| 6 months | -46.35% | ||
| Current year | -44.77% |
1 week
13.31
14.31
1 month
13.3118.30
Current year
13.3125.25
1 year
13.3132.66
3 years
13.31109.77
5 years
7.64109.77
10 years
7.04109.77
| Managers | Title | Age | Since |
|---|---|---|---|
Nian Feng Ju
CEO | Chief Executive Officer | 52 | 10-12-31 |
Hui Chen
DFI | Director of Finance/CFO | 45 | 22-04-21 |
Yong Qing Tan
CHM | Chairman | 69 | 19-04-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Gang Yuan
BRD | Director/Board Member | 57 | 21-08-04 |
Nian Feng Ju
CEO | Chief Executive Officer | 52 | 10-12-31 |
Hui Zeng
BRD | Director/Board Member | 44 | 10-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-11 | 13.89 | +2.36% | 7,159,171 |
| 24-06-07 | 13.57 | +0.59% | 5,517,712 |
| 24-06-06 | 13.49 | -4.87% | 9,381,571 |
| 24-06-05 | 14.18 | -0.98% | 4,729,969 |
| 24-06-04 | 14.32 | +0.14% | 5,026,331 |
End-of-day quote Shenzhen S.E., June 10, 2024
More quotes
Porton Pharma Solutions Ltd., formerly Porton Fine Chemicals Ltd., is a China-based company principally engaged in the provision of customized pharmaceutical research and production services. The Company is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The Company operates its businesses in Europe, North America, Asia and China, among others.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
13.89
CNY
Average target price
26.65
CNY
Spread / Average Target
+91.86%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.77% | 1.05B | |
| +48.53% | 780B | |
| +40.67% | 627B | |
| -6.37% | 353B | |
| +20.93% | 334B | |
| +8.21% | 296B | |
| +16.75% | 244B | |
| -1.19% | 217B | |
| +10.85% | 214B | |
| +4.40% | 161B |
- Stock Market
- Equities
- 300363 Stock
